No Detail Found!

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co- existence in Philadelphia positive CML patients

Author(s)
Nasir Ahmad Institue of Basic Medical Sciences, Khyber Medical University (IBMS-KMU),Peshawar, KP,Pakistan
Saima Qayum Institue of Basic Medical Sciences, Khyber Medical University (IBMS-KMU),Peshawar, KP,Pakistan
Abid Jameel Medical Teaching Institute, Hayatabad Medical Complex (MTI-HMC),Hayatabad, Peshawar, KP,Pakistan
Asif Ali Institute of Pathology and Diagnostic Medicine, Khyber Medical University (IPDM-KMU), Peshawar, KP, Pakistan;Institute of Pathology and Diagnostic Medicine, Khyber Medical University (IPDM-KMU), Peshawar, KP, Pakistan
Sami Siraj Institue of Basic Medical Sciences, Khyber Medical University (IBMS-KMU),Peshawar, KP,Pakistan
Johar Ali Center for Genomic Sciences, Rehman Medical Institute (RMI),Hayatabad, Peshawar, KP,Pakistan
Yasar Mehmood Yousafzai Institute of Pathology and Diagnostic Medicine, Khyber Medical University (IPDM-KMU), Peshawar, KP, Pakistan;Institute of Pathology and Diagnostic Medicine, Khyber Medical University (IPDM-KMU), Peshawar, KP, Pakistan
Abstract
Chronic Myeloid Leukaemia (CML) is characterized by BCR-ABL1 mutation. A number of research studies have published reports of concomitant JAK2-V617F mutation in BCR-ABL positive Chronic Myeloid Leukaemia. This study aims to investigate the frequency of JAK2-V617F mutation in BCR-ABL positive CML cases. After approval from ethical committee, participants were enrolled in the study. A total of 103 samples from CML patients were analysed for the presence of JAK2-V617F mutation using real-time polymerase chain reaction. Patients were monitored for treatment response using real-time quantitative PCR for BCR-ABL1 mutation. Out of 103 samples analysed, 2 patients tested positive for JAK2-V617F mutation. These two patients when treated with standard Tyrosine Kinase Inhibitors (TKI) therapy achieved molecular response and normalized the haemoglobin and white cell counts. However, one patient has sustained thrombocytosis. JAK2 remained positive throughout the treatment course. We could not follow the second patient till the end of the study. JAK2 mutation in BCR-ABL1 mutated CML appears to be rare. Treatment with TKI does not appear to reduce JAK2 mutation burden despite a decrease in BCR-ABL1 copy numbers.
Publication Details
Page(s) 2289-2295
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP6, Year: 2021

Request the full text from PASTIC

Keywords
Ph+ leukaemia, MPN and BCR-ABL, BCR-ABL and JAK2, JAK2 V617F, Chronic myeloid leukaemia
References
Aeed MZ,Ibrahim IK,Elamin HA,Ali EW .2014 .Coexistence of Jak2v617f mutation and philadelphia chromosome in sudanese patients with chronic myeloid leukemia. AJRC., 2(12) : 128-140.
Al-Kaabi MHAA,Al-Obaidy YGY,Sabir SF,AlKadmy MS SF .2013 .Incidence of Jak2 V617f mutation in Iraqi patients with Philadelphia positive Cml. Mintage J. Pharm. Med. Sci., 2(4) : 10-12.
Antonioli E,Carobbio A,Pieri L,Pancrazzi A,Guglielmelli P,Delaini F,Ponziani V,Bartalucci N,Tozzi L,Bosi A .2010 .Hydroxyurea does not appreciably reduce Jak2 V617f allele burden in patients with polycythemia vera or essential thrombocythemia. , 95(8) : 1435-1438.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz M J,Le Beau MM,Bloomfield CD,Cazzola M .2016 .The 2016 revision to the World Health Organization Classification of myeloid neoplasms and acute leukemia. Blood, 127(20) : 2391-2405.
Azonbakin S,Houssou B,Azannai I,Awede B,Massi R,Adjagba M,Agbalinsou A,Anani L,Darboux R,Gangbo F R .2018 .The Jak2 V617f mutation in chronic myeloid leukaemia within a bcr-abl positive cohort of beninese patients. Int. Blood Res. Rev., 8(1) : 1-6.
Baccarani M,Deininger MW,Rosti G,Hochhaus A,Soverini S,Apperley JF,Cervantes F,Clark RE,Cortes JE,Guilhot F JE .2013 .European leukemianet recommendations for the management of chronic myeloid leukemia: 2013. , 122(6) : 872-884.
Dreiling Bader G,B Bader G .2019 .Concurrent Jak2-positive myeloproliferative disorder and chronic Myelogenous leukemia: A novel entity? A case report with review of the literature. J. Investig. Med. High Impact Case Rep.,, 7 : 1-5.
Beillard E,Pallisgaard N,Van Der Velden V,Bi W,Dee R,Delabesse E,Macintyre E,Gottardi E,Saglio E,G E,Pcr E .2003 .-A Europe against cancer program. Leukemia, 17(12) : 2474-2486.
Bench AJ,White HE,Foroni L,Godfrey AL,Gerrard G,Akiki S,Awan A,Carter I,Goday‐Fernandez A,Langabeer SE .2013 .Molecular diagnosis of the myeloproliferative neoplasms: UK Guidelines for the detection of Jak 2 V 617 F and other relevant mutations. br. J. Haematol, 16091 : 25-34.
Frikha R,Turki F,Kassar O,Elloumi M,Kamoun H M,Oncol M .2021 .Co-Existence Of Bcr-Abl and Jak2v617f mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation? J. , 27(7) : 1784-1789.
Gabert J,Beillard E,Van Der Velden V,Bi W,Grimwade D,Pallisgaard N,Barbany G,Cazzaniga G,Cayuela JM,Cave H JM .2003 .Standardization and quality control studies of 'Real-Time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in LeukemiaA Europe against cancer program. Leukemia, 17(12) : 2318-2357.
Harrison C,Kiladjian JJ,Al-Ali HK,Gisslinger H,Waltzman R,Stalbovskaya V,Mcquitty M,Hunter DS,Levy R,Knoops L R .2012 .Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Eng. J. Med, 366(9) : 787-798.
Inami M,Inokuchi K,Okabe M,Kosaka F,Mitamura Y,Yamaguchi H,Dan K H .2007 .Polycythemia associated with the Jak2v617f mutation emerged during treatment of chronic myelogenous leukemia. Leukemia, 21 : 1103-1104.
Inami M,Yamaguchi H,Hasegawa S,Mitamura Y,Kosaka F,Kobayashi A,Kimura S,Dan K,Inokuchi K K .2008 .Analysis of the exon 12 and 14 mutations of the Jak 2 gene in Philadelphia chromosome-positive leukemia. Leukemia, 22 : 216.
Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Leibundgut EO,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G .2013 .V617f-Associated myeloproliferative neoplasms: A joint European Leukemianet/ Mpn&Mpnr-Euronet (Cost Action Bm0902) Study. , 27(10) : 2032-2039.
Kim B,Lee KT,Yoon YA,Choi YJ .2020 .Clinical significance of myeloproliferative neoplasms with Jak2v617f mutations and major Bcr-Abl1 Translocations: A literature review with case presentation. Blood Res., 55(1) : 62-65.
Lewandowski K,Gniot M,Wojtaszewska M,Kanduła Z,Becht R,Paczkowska E,Medras E,Wasilewska E,Iwoła M .2018 .Coexistence of Jak2 or calr mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Int. J. Lab. Hematol., 40(3) : 366-371.
Lorenzo M,Grille S,Stevenazzi M .2020 .Emergence of Bcr-Abl1 chronic myeloid leukemia in a Jak2-V617f polycythemia vera. J. Hematol., 9(1) : 23-29.
Martin-Cabrera P,Haferlach C,Kern W,Schnittger S,Haferlach T .2017 .Bcr-Abl1-Positive and Jak2 V617f-Positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br. J. Haematol., 176(1) : 135-139.
Mirza I,Frantz C,Clarke G,Voth AJ,Turner R .2007 .Transformation of polycythemia vera to chronic myelogenous leukemia. Arch. Pathol. Lab. Med, 131(11) : 1719-1724.
Soderquist CR,Ewalt MD,Czuchlewski DR,Geyer JT,Rogers HJ,Hsi ED,Wang SA,Bueso-Ramos CE,Orazi A,Arber DA .2018 .Myeloproliferative neoplasms with concurrent Bcr-Abl1 translocation and Jak2 V617f mutation: A multi-institutional study from the bone marrow pathology group. Modern Pathology, 31(5) : 690-704.
Sweet K,Hazlehurst L,Sahakian E,Powers J,Nodzon L,Kayali F,Hyland K,Nelson A,Pinilla-Ibarz J .2018 .A Phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res, 74 : 89-96.
Tabassum N,Saboor M,Ghani R,Moinuddin M .2014 .Frequency of Jak2 V617f mutation in patients with Philadelphia positive chronic myeloid leukemia in Pakistan. Pak. J. Med. Sci., 30(1) : 185-188.
Tefferi A,Pardanani A .2015 .Myeloproliferative neoplasms: A contemporary review. JAMA Oncol, 1(1) : 97-105.
Toni LS,Garcia AM,Jeffrey DA,Jiang X,Stauffer BL,Miyamoto SD,Sucharov CC .2018 .Optimization of phenol-chloroform RNA extraction. Methodsx, 5 : 599-608.
Valikhani A,Poopak B,Ferdowsi S,Azizi Tabesh G,Ghaffari SH,Saraf Kazeruoni E,Rezaei N,Farshchi A,Amirizadeh N A .2017 .Asxl1 and Jak2v617f gene mutation screening in Iranian patients with chronic myeloid leukemia. Asia Pac. J. Clin. Oncol., 13(2) : E41-E47.
Zaen-Al-Abideen Pahore TS,Shamsi MT,Tasneem Farzana SH,Nadeem M,Ahmad M,Naz A .2011 .Jak2v617f mutation in chronic myeloid leukemia predicts early disease progression. J Coll Phys Surg Pak, 21(8) : 472-475.
Zhou A,Knoche E,Engle E,Fisher D,Oh S D .2015 .Concomitant Jak2 V617f-Positive polycythemia vera and Bcr-Abl-Positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J, 5(10) : E351-E351.
0

Citations

0

Downloads

10

Views